Proactive Investors - Run By Investors For Investors

Constellation Healthcare Technologies beefs up board

Dr Zimberg was one of the founding partners of a biotech-focused merchant bank
Constellation Healthcare Technologies beefs up board
Dr Zimberg is a highly-respected radiation oncology specialist

US-based healthcare services provider Constellation Healthcare Technologies (LON:CHT) has appointed highly respected physician Dr Shawn Zimberg to the board as a non-executive director.

Dr Zimberg is the medical director of Advanced Radiation Centers of New York, a division of Integrated Medical Professionals, and has served on the board of Integrated Medical Professionals since July 2006.

Constellation said he is a leading expert in the field or radiation oncology. He was also one of the founding partners of Evolution Partners, a merchant and investment bank focused on life sciences, biotechnology and healthcare & wellness industries.

"He is a highly respected physician and entrepreneur. His addition will help us greatly as we pursue our strategy of being one of the leading healthcare services and technology businesses in the US,” said Paul Parmar, chief executive officer of Constellation.

“Constellation will benefit from his medical insight, especially in the billing and practice management verticals of our business. Constellation will also gain from Dr Zimberg's broader knowledge of the US healthcare sector, its pressure points and how the company can optimise its positioning in-front of the medical community, " Parmar added.


Register here to be notified of future CHT Company articles
View full CHT profile

Constellation Healthcare Technologies, Inc. Timeline

Related Articles

November 16 2016
Pressure BioSciences' product and services revenues picked up in the third quarter to a record high and touched above $500mln for the first time in any quarter - while lower expenses helped lead to a lower operating loss, the company said on Wednesday
January 13 2016
If everyone could be as active as the York-based outfit there would not be such a pressing demand for its products.
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.